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Reduction in Subtypes and Sizes of Myocardial Infarction With
Ticagrelor in PEGASUS–TIMI 54
Marc P. Bonaca, MD, MPH; Stephen D. Wiviott, MD; David A. Morrow, MD, MPH; P. Gabriel Steg, MD; Christian Hamm, MD;
Deepak L. Bhatt, MD, MPH; Robert F. Storey, MD; Marc Cohen, MD; Julia Kuder, BS; KyungAh Im, PhD; Giulia Magnani, MD;
Andrzej Budaj, MD; Jose C. Nicolau, MD; Alexander Parkhomenko, MD; Jose Lopez-Sendon, MD; Mikael Dellborg, MD; Rafael Diaz, MD;
Frans Van de Werf; Ramon Corbalan, MD; Assen Goudev, MD; Eva C. Jensen, MD; Per Johanson, MD; Eugene Braunwald, MD;
Marc S. Sabatine, MD, MPH
Background-—Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS-
TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With
Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin). MI can occur in diverse settings and with
varying severity; therefore, understanding the types and sizes of MI events prevented is of clinical importance.
Methods and Results-—MIs were adjudicated by a blinded clinical events committee and categorized by subtype and fold
elevation of peak cardiac troponin over the upper limit of normal. A total of 1042 MIs occurred in 898 of the 21 162 randomized
patients over a median follow-up of 33 months. The majority of the MIs (76%) were spontaneous (Type 1), with demand MI (Type
2) and stent thrombosis (Type 4b) accounting for 13% and 9%, respectively; sudden death (Type 3), percutaneous coronary
intervention–related (Type 4a) and coronary artery bypass graft–related (Type 5) each accounted for <1%. Half of MIs (520, 50%)
had a peak troponin ≥10x upper limit of normal and 21% of MIs (220) had a peak troponin ≥1009 upper limit of normal. A total
of 21% (224) were ST-segment–elevation MI STEMI. Overall ticagrelor reduced MI (4.47% versus 5.25%, hazard ratio 0.83, 95%
conﬁdence interval 0.72–0.95, P=0.0055). The beneﬁt was consistent among the subtypes, including a 31% reduction in MIs
with a peak troponin ≥1009 upper limit of normal (hazard ratio 0.69, 95% conﬁdence interval 0.53–0.92, P=0.0096) and a 40%
reduction in ST-segment elevation MI (hazard ratio 0.60, 95% conﬁdence interval 0.46–0.78, P=0.0002).
Conclusions-—In stable outpatients with prior MI, the majority of recurrent MIs are spontaneous and associated with a high bio-
marker elevation. Ticagrelor reduces the MI consistently among subtypes and sizes including large MIs and ST-segment elevation MI.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01225562. ( J Am Heart Assoc. 2018;7:
e009260. DOI: 10.1161/JAHA.118.009260)
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P
atients with prior myocardial infarction (MI) are at long-
term heightened risk of recurrent ischemic events.1
PEGASUS-TIMI 54 (Prevention of Cardiovascular Events [eg,
Death From Heart or Vascular Disease, Heart Attack, or
Stroke] in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin) demon-
strated that long-term secondary prevention with ticagrelor,
added to aspirin, reduced the primary composite end point of
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MI, stroke, or cardiovascular death by 15%.2 Overall, the
magnitude of relative risk reduction was similar for all of the
components of the composite end point, including cardiovas-
cular death and ischemic stroke; however, the most frequent
outcome was recurrent MI.
The deﬁnition and natural history of MI has evolved over the
past decade.3 Themeasurement of circulating cardiac troponin,
measured with increasingly sensitive assays that are able to
detect very small levels ofmyocardial injury, has becomecentral
to the diagnosis of MI. Because of the increasing sensitivity of
troponin assays, events categorized as MI reﬂect a broadening
spectrum of events in terms of cause, size, and severity.4 In
addition, events reported in clinical trials may differ from those
commonly coded in public data sets.5 In acute populations
undergoing intervention, for example, serial biomarkers may
detect largelyproceduralMI, althoughdifferentiatingprocedural
injury from index events may be challenging.6–8 Understanding
and further characterizing MI events is therefore important in
understanding their clinical signiﬁcance, particularly in the
context of therapies with safety concerns such as bleeding.9
We hypothesized that in the stable high-risk PEGASUS-TIMI
54 population, recurrent MI would be largely spontaneous and
associated with signiﬁcant elevation in circulating cardiac
biomarkers. In addition, we hypothesized that the beneﬁts of
ticagrelor for reducing MI would be present across cause and
size of MI but would be particularly notable for MI clearly
mediated by coronary thrombosis such as ST-segment–
elevation MI (STEMI).
Methods
Study Population
PEGASUS-TIMI 54 randomized patients with prior MI to
ticagrelor 60 mg twice daily, ticagrelor 90 mg twice daily,
or placebo, all on a background of low-dose aspirin. The
protocol was approved by the relevant ethics committee at
each participating site. Written informed consent was
obtained from all the patients. The design10 and primary
results of the trial have been published.2 Patients aged at
least 50 years were enrolled with a spontaneous MI
occurring 1 to 3 years before enrollment and at least 1
of the following additional high-risk features: age ≥65 years,
diabetes mellitus requiring medication, a second prior
spontaneous MI, multivessel coronary artery disease, or
chronic renal dysfunction, deﬁned as a creatinine clearance
<60 mL/min as estimated by the Cockroft-Gault equation.
Patients were ineligible if there was planned use of a P2Y12
receptor antagonist or anticoagulant therapy during the
study period; if they had a bleeding disorder, a history of
intracranial bleeding, a central nervous system tumor, or an
intracranial vascular abnormality; or if they had had
gastrointestinal bleeding within the previous 6 months or
major surgery within the previous month.
End Points
The primary efﬁcacy end point was MI, and subtypes of MI in
this article. All potential events were adjudicated by a clinical
events committee, which was blinded to treatment allocation.
All conﬁrmed MI events were further categorized by the clinical
events committee into clinical subtype as deﬁned in the
Universal Deﬁnition of MI as well as the associated peak
troponin elevation (available in 88%). Stent thrombosis (Type
4b MI) was adjudicated through collection and formal review of
coronary angiograms. Type 2 MI events had to meet criteria for
a spontaneous MI as deﬁned in the charter, not meet criteria
for another MI subtype, and had to occur in the setting of a
clinical picture consistent with ischemia caused by either
increased oxygen demand or decreased supply, (eg, coronary
artery spasm, coronary embolism, anemia, arrhythmias, hyper-
tension, or hypotension). Although even low-level elevations in
cardiac troponin have been associated with adverse prognosis
in patients with acute coronary syndrome,11 elevations of at
least 10-fold have generally been regarded as indicating larger
events and enable detection of important events in the setting
of procedures such as bypass surgery.3 In order to evaluate the
consistency of beneﬁt for ticagrelor across MI size, serial
thresholds were examined also including 259, 509, 1009,
and 2009 the upper limit of normal. In addition, events were
categorized into the core clinical categories of STEMI and non–
ST segment–elevation MI with ECGs collected by the clinical
Clinical Perspective
What Is New?
• Debates regarding the duration of dual antiplatelet therapy
often center around the concept of stent protection.
• This article demonstrates that in high-risk patients with prior
myocardial infarction (MI), recurrent events are primarily
large, spontaneous, de novo events rather than stent
thrombosis and that long-term ticagrelor consistently
reduces recurrent MI regardless of size or cause.
What Are the Clinical Implications?
• When evaluating patients for long-term secondary pre-
vention with ticagrelor, patient risk proﬁle should be
considered.
• High-risk patients with prior MI have long-term risk of
recurrent spontaneous events including large MIs and ST-
segment–elevation MI.
• Long-term ticagrelor signiﬁcantly reduces MI regardless
of cause including large MIs, ST-segment–elevation
MI, and the composite of fatal MI or sudden cardiac death.
• These ﬁndings should be considered when weighing the
risks and beneﬁts of long-term therapy with ticagrelor.
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events committee (in 1021 of 1042 or 98.6% of events).
Additional efﬁcacy end points included fatal MI, sudden cardiac
death (presumed largely coronary in origin in a post-MI
population) and the combination of these 2.
Statistical Considerations
Cumulative event rates at 3 years following randomization
were calculated by the complement of Kaplan–Meier survival
estimates. The treatment comparisons were based on the Cox
proportional-hazards model including treatment assignment
as an indicator variable. Since this was a large randomized
trial, no additional adjustment was made in this model. We
have also examined the risks of MI and subtypes of MI in the
context of competing risks for consistency. The proportional
hazards assumption was assessed by creating an interaction
of the treatment assignment indicator and a function of
survival time and included in the model. All models met this
assumption. Efﬁcacy analyses were performed on an inten-
tion-to-treat basis. Patients could have more than 1 MI during
follow-up, so analyses evaluating subtypes of MI included the
ﬁrst MI of that subtype. The data for this analysis will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. The analytic
methods are described and the study materials (trial protocol)
have been published with primary results. Results are
summarized by hazard ratios and 95% conﬁdence intervals
and all reported P values are 2-sided. No adjustment was
made for the signiﬁcance level for multiple testing. Analyses
were performed using SAS v9.4 (SAS Institute Inc, Cary, NC)
and R software version 3.2.2 (www.r-project.org).
Results
A total of 21 162 patients were randomized with 7067 to
placebo, 7045 to ticagrelor 60 mg twice daily, and 7050 to
ticagrelor 90 mg twice daily. A total of 1042 MI events
occurred in a total of 898 patients at a median of 460 days
(interquartile range 222–721) following randomization.
Patients who had MI during the trial were older, had a greater
prevalence of risk factors, had more severe vascular disease,
and were more likely to have had an index non–ST segment–
elevation MI relative to STEMI (Table S1). For patients
randomized to placebo, the rate of recurrent MI at 3 years
was 5.2% or 1.7% annualized.
Types and Sizes of MI
The majority of MI events that occurred during follow-up were
spontaneous atherothrombotic (76%, Type 1, Figure 1A). A
minority were secondary to demand (13%, Type 2) or stent
thrombosis (9%, Type 4b). Only 6 MI events were associated
with troponin elevation in the setting of percutaneous
intervention (Type 4a) and there was 1 MI event occurring
in the setting of coronary artery bypass surgery (Type 5).
When evaluating by subtype in the placebo arm, the highest
rate was for spontaneous MI (4.1%, Figure S1). Rates of all
other subtypes were <1% over 3 years (Figure S1).
There was a broad distribution of peak troponin elevation
associated with MI events (Figure 1B). The majority of MI
events were associated with a peak troponin elevation of 10
times the upper limit of normal or more.
Efﬁcacy of Ticagrelor
Both doses of ticagrelor signiﬁcantly reduced the risk of MI
(ticagrelor 60 mg, hazard ratio (HR) 0.84, 95% conﬁdence
interval (CI) 0.72–0.98, P=0.031; ticagrelor 90 mg, HR 0.81,
95%CI 0.69–0.95, P=0.010). The effect of ticagrelor at reducing
MI was evident early and continued through the 3 years of
follow-up (Figure 2). When stratifying by the Universal Deﬁni-
tion of Myocardial Infarction subtypes (Figure 3), the beneﬁt of
ticagrelor appeared consistent for spontaneous (Type 1),
demand (Type 2), and angiographically veriﬁed stent-thrombo-
sis-related (Type 4b) with insufﬁcient numbers of Type 3 (n=7),
Type 4a (n=6), and Type 5 (n=1) MI to evaluate efﬁcacy.
When evaluating by peak troponin as a measure of MI size,
there was a consistent beneﬁt with ticagrelor with increasing
elevation of peak troponin (Figure 4). This included a 31% risk
reduction in MIs with at least a 100-fold elevation of peak
troponin (ticagrelor doses pooled, HR 0.69, 95% CI 0.53–0.92;
ticagrelor 60 mg, HR 0.63, 95% CI 0.45–0.89; ticagrelor
90 mg, HR 0.76, 95% CI 0.55–1.04, Figure 4). The proportion
of ﬁrst MI events with a troponin elevation ≥50 times the upper
limit of normal was signiﬁcantly lower with ticagrelor versus
placebo (30% versus 37%, P=0.049), with the difference even
greater for spontaneous (Type 1) MIs with a troponin elevation
≥50 times the upper limit of normal (27% versus 36%, P=0.019).
MI was also stratiﬁed by the core clinical subtypes of
STEMI and non–ST-segment–elevation MI. Patients random-
ized to placebo experienced STEMI at a roughly linear rate
during follow-up with no apparent plateau over time (Fig-
ure 5). Ticagrelor signiﬁcantly reduced STEMI by 40% (tica-
grelor doses pooled: HR 0.60, 95% CI 0.46–0.78, P=0.0002),
with consistent efﬁcacy with both the 60 mg and 90 mg
ticagrelor doses (Figure 5). The incidence of non–ST seg-
ment–elevation MI also tended to be lower (ticagrelor doses
pooled: HR 0.91, 95% CI 0.77–1.06).
Fatal MI or Sudden Cardiac Death
A total of 330 patients had a fatal MI (n=61, 5.85% of all MIs)
or sudden cardiac death (n=269). Ticagrelor reduced the risk
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of these events by 23% (HR 0.77, 95% CI 0.62–0.96,
P=0.020), with similar effects on fatal MI (HR 0.72, 95% CI
0.43–1.20) and on sudden cardiac death (HR 0.78, 95% CI
0.61–0.997, Figure S2).
Discussion
This analysis demonstrates 3 major ﬁndings: ﬁrst, that the
risk of recurrent MI over 3 years in well-treated patients with
history of MI >1 year prior exceeds 5% (1.7% per year);
Figure 1. A, Distribution of myocardial infarction events occurring during follow-up by Universal Deﬁnition
of MI subtype. B, Distribution of myocardial infarction events occurring during follow-up by fold elevation in
peak biomarker (includes 913 events with troponin available). CABG indicates coronary artery bypass
grafting surgery; MI, myocardial infarction; PCI, percutaneous coronary intervention; Tn, troponin; ULN,
upper limit of normal.
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secondly, that even in the era of sensitive troponin assays,
these recurrent events in stable secondary prevention pop-
ulations are largely new spontaneous events and that
demand-related myocardial injury and stent complications
accounted for only a minority of MIs; and ﬁnally, that long-
term treatment with ticagrelor on a background of aspirin
Figure 2. Myocardial infarction occurring over 3 years by randomized treatment. CI indicates conﬁdence
interval; HR, hazard ratio; MI, myocardial infarction.
Figure 3. Reduction in MI by treatment (red—ticagrelor 90 mg twice daily, blue—ticagrelor 60 mg twice
daily, purple—ticagrelor doses pooled) for MI overall and by MI subtype. CI indicates conﬁdence interval;
HR, hazard ratio; KM, Kaplan–Meier; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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signiﬁcantly reduces the incidence of recurrent MI by 15% to
20%, reduces STEMI by 40%, and reduces the risk of fatal MI
or sudden cardiac death by 23%.
In PEGASUS-TIMI 54, patients were purposely selected in
the stable phase at least 1 year from MI.2 Patients who were
unstable, critically ill, or planned for procedures were
Figure 4. Reduction inMI by treatment (red—ticagrelor 90 mg twice daily, blue ticagrelor 60 mg twice daily,
purple—ticagrelor doses pooled) forMI overall and by fold elevation of peak biomarker. CI indicates conﬁdence
interval; HR, hazard ratio; KM, Kaplan–Meier; MI,myocardial infarction; Tn, troponin; ULN, upper limit of normal.
Figure 5. STEMI occurring over 3 years by randomized treatment. CI indicates conﬁdence interval; HR,
hazard ratio; STEMI, ST-segment–elevation myocardial infarction.
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excluded. In addition, utilization of indicated background
therapy was high, with >99% using aspirin, >90% receiving
statins, and >80% on b-blockers. Nevertheless, recurrent MI
continued to occur at a roughly linear rate even 3 years after
randomization. This observation underscores the ongoing risk
of spontaneous plaque rupture in the post-MI population in
spite of intensive medical therapy.
When evaluating the rate of recurrent MI, it is important to
understand the subtype of event. As troponin has evolved to
become the key component of the deﬁnition of MI and as
troponin assays have continued to improve in sensitivity and
speciﬁcity, there is debate about the clinical relevance of MI,
particularly when occurring in the context of critical illness
(demand or Type 2 MI) or elective percutaneous coronary
intervention (procedural or Type 4 MI).4,12 Although degree of
biomarker elevation may represent several factors beyond the
event itself (eg, time to diagnosis, door-to-balloon time), more
than half of the MI events that occurred were associated with
cardiac biomarker levels more than 109 the upper limit of
normal. The current analysis demonstrates that the majority
of MI events ascertained and adjudicated in a modern clinical
trial are spontaneous and associated with signiﬁcant elevation
in circulating biomarkers.
Long-term secondary prevention with ticagrelor 60 mg
twice daily or 90 mg twice daily signiﬁcantly reduced the risk
of recurrent MI by 15% to 20%. This beneﬁt was consistent
when restricting to only spontaneous (Type 1) MIs as well as
when restricting to large MIs with a 100-fold or greater
elevation of cardiac troponin. Although there is debate as to
the meaning of biomarker cut points in determining the
severity of MI, STEMI is broadly recognized as a severe, life-
threatening event. We observed that the beneﬁt of ticagrelor
appeared of even greater magnitude for STEMI with a 40%
reduction, an observation that is intuitive given the high levels
of platelet P2Y12 receptor inhibition achieved by both doses of
ticagrelor and the important role of the platelet P2Y12
receptor in amplifying and sustaining arterial thrombus
sufﬁciently to achieve complete arterial occlusion.13–15
The beneﬁt of ticagrelor in reducing STEMI and large MI
translated into a reduction in MI-related mortality either as
fatal MI or sudden death. These data support the position that
potent antithrombotic strategies in high-risk populations have
the potential to reduce the mortality related to MI even
beyond the beneﬁts of currently utilized preventive strategies.
There are several limitations to this analysis. Systemic
serial sampling of biomarkers was not performed after
coronary interventions, which may have led to underascer-
tainment of periprocedural (percutaneous coronary interven-
tion or coronary artery bypass grafting surgery) MI. This,
however, would lead to an underestimate of overall risk and
might underestimate the absolute beneﬁt of ticagrelor in this
population. During the course of the trial, the Third Universal
Deﬁnition of MI was published and modiﬁed the deﬁnition of
Type 4a MI and added Type 4c MI (because of restenosis).
Type 4a was made more stringent, increasing the threshold of
troponin to 59 upper limit of normal and requiring additional
evidence of ischemia (eg, syndrome, angiographic evidence,
ECG changes); however, because there were only 6 Type 4a
MIs, this change would not impact the ﬁndings of this analysis
and therefore events were not re-adjudicated with the
updated deﬁnition. In addition, Type 4c MI was not captured.
Similarly, there are limitations with the deﬁnition and the
ability to discriminate Type 2 MI from other subtypes. As
outlined in the Methods section, events classiﬁed as Type 2
MI had to meet criteria as an MI and had to occur in a setting
consistent with supply–demand mismatch. Nonetheless, it is
possible that some of these events were primarily thrombotic
in cause or had a thrombotic component, an observation that
would be supported by the trend towards beneﬁt with
ticagrelor in this analysis. Overall, only 13% of MI events
were classiﬁed as Type 2 and inclusion of some Type 1 events
would only reduce frequency in this population, underscoring
the observation that Type 1 events are the predominant cause
of MI in this population. An additional limitation is the use of
different troponin assays of differing sensitivity across sites.
Utilization of high thresholds (eg, 100-fold elevations) in peak
troponin was intended to select for large events regardless of
assay, and differing assays would not impact the consistent
ﬁndings shown with STEMI.
Conclusions
In stable outpatients with a history of MI, the majority of
recurrent MI events are spontaneous and associated with a
high biomarker elevation. Ticagrelor signiﬁcantly reduces the
incidence of MI consistently among different subtypes and
biomarker sizes, with the greatest absolute reduction in
spontaneous MIs, large MIs, and STEMI.
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Table S1. Baseline Characteristics by Recurrent Myocardial Infarction.  
 
 
SD-standard deviation, mmHG-millimeters of mercury, eGFR-estimated glomerular filtration rate, MDRD- 
Modification of Diet in Renal Disease, PAD-peripheral artery disease, CHF-congestive heart failure, MI-
myocardial infarction, CABG-coronary artery bypass grafting surgery, PCI-percutaneous intervention, DES-drug 
eluting stent, NSTEMI-non-ST elevation myocardial infarction  
Characteristic No MI MI p-value 
  N=20,264 N=898   
    
Age, mean (SD) 65.3 (8.32) 66.2 (9.02) 0.0027 
Female, n(%) 4842 (23.89%) 218 (24.28%) 0.7931 
Body Mass Index, median (range) 
27.8  
(25.14, 31.14) 
28.4  
(25.31, 31.59) 0.0248 
SBP (mmHg), mean (SD) 132.5 (16.89) 135.1 (18.72) 0.0002 
    
History Hypertension, n (%) 15660 (77.29%) 747 (83.18%) <.0001 
History of Hypercholesterolaemia, n (%) 15540 (76.7%) 701 (78.06%) 0.3452 
Current Smoker, n (%) 3347 (16.52%) 189 (21.05%) 0.0004 
History of Diabetes, n (%) 6439 (31.78%) 367 (40.87%) <.0001 
eGFR < 60 (MDRD), n (%) 4570 (22.84%) 279 (31.38%) <.0001 
    
History of PAD, n (%) 1057 (5.22%) 86 (9.58%) <.0001 
History of Atrial Fibrillation, n (%) 809 (3.99%) 58 (6.46%) 0.0003 
History of CHF, n (%) 4005 (19.77%) 221 (24.61%) 0.0004 
Prior Angina, n (%) 6196 (30.58%) 359 (39.98%) <.0001 
Multivessel Coronary Artery Disease, n (%) 11959 (59.03%) 599 (66.7%) <.0001 
History of Second Prior MI, n (%) 3201 (15.8%) 298 (33.18%) <.0001 
Prior CABG, n (%) 842 (4.16%) 133 (14.81%) <.0001 
History of PCI with stenting, n (%) 16184 (80.15%) 707 (78.82%) 0.3296 
Prior PCI with DES (1=Yes, 0=No), n (%) 7880 (48.69%) 409 (57.85%) <.0001 
Qualifying MI: NSTEMI, n (%) 8124 (40.14%) 459 (51.11%) <.0001 
    
    
Region     <.0001 
North America, n (%) 3680 (18.16%) 227 (25.28%)   
South America, n (%) 2372 (11.71%) 86 (9.58%)   
Western Europe (incl. S Af), n (%) 5847 (28.85%) 291 (32.41%)   
Eastern Europe, n (%) 6066 (29.93%) 224 (24.94%)   
Asia/Australia/New Zealand, n (%) 2299 (11.35%) 70 (7.8%)   
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Figure S1. Cumulative incidence of myocardial infarction subtypes occurring in patients 
randomized to placebo (on aspirin monotherapy) during follow up. 
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Figure S2. Ticagrelor and fatal myocardial infarction, sudden cardiac death and the 
composite of both. 
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